Trial Profile
A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jan 2023
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- Sponsors Ipsen
- 14 Dec 2022 According to Ipsen media release, the company has presented the data from this study in the 12th World Congress for Neurorehabilitation (WCNR).
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 22 Apr 2021 Interim results (n=201) presented at the 73rd Annual Meeting of the American Academy of Neurology.